Key Takeaways
- Lupin’s subsidiary VISUfarma has secured an exclusive license to commercialize YUVEZZI™ (carbachol + brimonidine tartrate ophthalmic solution 2.75%/0.1%) in the European Union, United Kingdom, Switzerland, Norway, and Iceland.
- The agreement includes a strategic investment by VISUfarma in Visus Therapeutics, plus potential regulatory and commercial milestone payments and tiered royalties based on net sales.
- YUVEZZI™ is the first and only once‑daily, dual‑agent eye drop approved by the U.S. FDA for treating presbyopia, offering a novel mechanism that constricts and stabilizes pupil size to improve near vision.
- Lupin’s CEO Vinita Gupta highlighted the deal as a boost to the company’s Specialty Care strategy and eye‑care franchise, while Tenpoint’s CEO Henric Bjarke emphasized the partnership’s role in expanding global access to YUVEZZI™.
- Both companies outline their broader corporate profiles: Lupin as a diversified global pharma leader with strong manufacturing and R&D capabilities; Tenpoint as a commercial‑stage ophthalmic firm focused on bringing YUVEZZI™ to the aging‑eye market worldwide.
Overview of the Partnership
On August 20, 2026, Lupin Limited announced that its wholly owned subsidiary VISUfarma B.V. had entered into an exclusive licensing agreement with Visus Therapeutics Inc., a wholly owned subsidiary of Tenpoint Therapeutics Holding Limited. The collaboration grants VISUfarma the sole right to undertake regulatory activities, commercialization, marketing, promotion, distribution, and sale of YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland. This move underscores a shared commitment to expand global access to the only once‑daily dual‑agent presbyopia‑correcting eye drop within the fast‑growing presbyopia vision‑management segment.
Financial Structure of the Deal
Under the terms of the agreement, VISUfarma will make a strategic investment in Visus Therapeutics. In addition, Tenpoint and Visus (individually or collectively) are eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based on net sales of YUVEZZI™ in the licensed territories. The financial framework is designed to align incentives, rewarding both parties for achieving development, approval, and commercial milestones while providing Lupin with a pathway to recoup its investment through sales‑linked royalties.
Leadership Perspectives
Vinita Gupta, Chief Executive Officer of Lupin, expressed enthusiasm about the partnership, stating that it advances Lupin’s Specialty Care strategy and builds on the earlier acquisition of VISUfarma. She noted that the deal strengthens Lupin’s vision‑care franchise and expands its presence across key European markets, reinforcing the company’s commitment to broadening access to differentiated therapies and improving patient outcomes. Henric Bjarke, CEO of Tenpoint, described the agreement as an important step toward making YUVEZZI™ available to millions of presbyopia patients worldwide, highlighting Lupin’s strong commercial operations in Europe and VISUfarma’s established eyecare presence as ideal complements to Tenpoint’s goals.
Product Profile: YUVEZZI™
YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is the first and only once‑daily, dual‑agent eye drop approved by the U.S. Food & Drug Administration for the treatment of presbyopia, a condition characterized by the gradual loss of near‑vision acuity that typically begins around age 45. The formulation combines two agents with complementary mechanisms: carbachol induces miosis (pupil constriction), which enhances depth of focus for near tasks, while brimonidine counters excessive pupil dilation, maintaining a stable pupil size under varying lighting conditions. Together, these actions improve close‑up vision without the need for multifocal lenses or surgical intervention.
Regulatory and Commercial Progress
Tenpoint is currently advancing the commercialization of YUVEZZI™ in the United States following its recent FDA approval. The company has also initiated regulatory pathways in other regions, having submitted a Mutual Recognition Procedure (MMA) in the United Kingdom via the MHRA’s International Recognition Procedure. Tenpoint plans to continue filing applications for YUVEZZI™ in additional key markets worldwide, leveraging the partnership with Lupin to navigate European regulatory processes and accelerate market entry.
About Lupin Limited
Lupin Limited, headquartered in Mumbai, India, is a global pharmaceutical leader with a robust presence across India, the United States, other developed markets, and emerging markets, distributing products in over 100 territories. The company’s diversified portfolio spans generics, complex generics, specialty medicines, and biosimilars. Lupin maintains strong leadership in the United States and India within core therapeutic areas such as cardiovascular, respiratory, diabetes, gastrointestinal, and women’s health. Its operations are supported by 15 state‑of‑the‑art manufacturing facilities, six research centers, and a workforce exceeding 26,000 professionals. Beyond traditional pharmaceuticals, Lupin expands the healthcare ecosystem through diagnostics, digital health initiatives, patient‑support programs, and disease‑management efforts, with sustainability remaining a core pillar of its business strategy.
About Tenpoint Therapeutics
Tenpoint Therapeutics Ltd. is a commercial‑stage ophthalmic pharmaceutical company dedicated to the commercialization of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual‑agent eye drop for treating presbyopia. The condition affects roughly 128 million people in the United States and approximately 2 billion individuals globally. Tenpoint focuses on understanding real‑world patient needs and collaborating with eye‑care professionals to bring innovative solutions to the aging‑eye market. Further information is available at https://tenpointtherapeutics.com, and the company maintains a LinkedIn presence at https://www.linkedin.com/company/tenpointtherapeutics/.
Safety Information for YUVEZZI™
Patients should not use YUVEZZI™ if they are allergic to any of its ingredients or if they currently have iritis (inflammation of the iris). Prior to use, individuals should inform their physician of any history of depression, low blood pressure, or circulation problems. The medication may cause temporary blurry, dim, or dark vision; therefore, activities such as driving, operating machinery, or engaging in hazardous tasks should be avoided if these visual disturbances occur. Caution is also advised for night driving or low‑light environments. Immediate medical attention is warranted if sudden flashes of light, floaters, or vision loss develop. The vial tip must not touch the eye, eyelid, or any surface to prevent contamination. The most frequently reported side effects include headache, impaired vision, and temporary eye pain or irritation upon administration; most of these events are mild, short‑lived, and resolve without intervention.
Conclusion and Outlook
The licensing agreement between Lupin’s VISUfarma and Tenpoint’s Visus Therapeutics represents a strategic move to bring a breakthrough presbyopia therapy to European patients while reinforcing both companies’ positions in the specialty ophthalmology arena. By combining Lupin’s extensive commercial infrastructure and VISUfarma’s established eyecare footprint with Tenpoint’s innovative product and regulatory expertise, the partnership aims to deliver YUVEZZI™ efficiently across the Licensed Territories. As presbyopia continues to affect a growing aging population worldwide, this collaboration has the potential to improve near‑vision outcomes for millions, expand access to a novel non‑surgical treatment option, and generate sustainable value for both organizations through milestone achievements and sales‑linked royalties. The forthcoming regulatory submissions and subsequent commercial launches will be critical milestones to watch in the evolving landscape of vision‑care therapeutics.